The new vaccine candidate, DIOS-CoVax2, uses banks of genetic sequences of all known coronaviruses, including those of bats, believing that they are the natural hosts of many siblings of human coronaviruses.
Phase 2 human trial of Oxford COVID-19 vaccine could begin tomorrow
A vaccine that clears all samples can then be delivered without pain in the skin without pain in the head by a jet injection of the spring.
“Our approach includes 3D computer modeling of the SARS-CoV-2 [Covid-19] virus’ structures. It uses information about the virus itself as well as its relatives – SARS, MERS and other coronaviruses carried by animals that threaten to ‘spill-over’ to humans again to cause future human epidemics, “said Professor Jonathan Heeney, head of the Laboratory of Viral Zoonotics at the University of Cambridge, and founder of DIOSynVax – a spin-out company from Cambridge.
“We are looking for chinks in their armor, crucial pieces of the virus that we can use to construct the vaccine to direct the immune response in the right direction. Finally, we want to create a vaccine that not only protects against SARS-CoV -2, but also other related coronaviruses that can be transmitted from animals to humans, “he said.
Prof Heeney said that his team’s strategy aims to bring him to the domains of the virus structure that are absolutely critical to docking with a cell, while avoiding the components that can make things worse. “What we end up with is a mimicry, a synthetic part of the virus minus those non-essential elements that can trigger a bad immune response,” he added.
His team has developed libraries of computer-generated antigen structures encoded by synthetic genes that can train the human immune system to target key regions of the virus and to produce beneficial anti-viral responses. These immune responses include neutralizing antibodies, which block virus infection, and T cells, which destroy virus-infected cells. This so-called “laser-specific” computer generated approach is able to help prevent the adverse hyper-inflammatory immune reactions that can be activated by recognizing the wrong parts on the surface of the coronavirus.
Oxford Covid Vaccine Update: This may be the first shot available to Indians
“Most research groups have used solid approaches to vaccine development because of the urgent need to tackle the pandemic. We all hope that current clinical trials have a positive outcome, but even successful vaccines are likely to have their limitations – they may not be suitable for vulnerable people, and we do not know how long their effects will last, for example, “said Dr Rebecca Kinsley, Chief Operating Officer of DIOSynVax and a postdoctoral researcher at the University of Cambridge.
“Our approach – using synthetic DNA to deliver custom-designed, immunoselected vaccine antigens – is revolutionary and is ideal for complex viruses such as coronavirus. If successful, it will result in a vaccine that must be safe for widespread use and that can be made and distributed at low cost, ‘she said. DIOS-CoVax2, which hopes to go through human trials later this year, is the latest vaccine candidate to be supported by the UK government with £ 1.9 million in funding as part of a collaboration between DIOSynVax, which is contributing an additional £ 400,000 to the process, the University of Cambridge and the University Hospital Southampton NHS Foundation Trust.
The team says that their proposed new vaccine can be lyophilized as a powder and is therefore heat stable, which means it does not need to be stored cold. This makes transportation and storage much easier, especially important in low- and middle-income countries, and it can be delivered through PharmaJet Tropis intradermal Needle-free Injection System, which delivers the vaccine in less than 1 / 10th of a second jet injection.
Professor Saul Faust, Director of the NIHR Southampton Clinical Research Facility, said: “It is particularly exciting that the clinical trial will provide the vaccine test through the skin of people with a device without needles, as combined with stable DNA fax technology can do this. an important breakthrough in being able to give a future vaccine to large numbers of people around the world. “The news comes when the University of Oxford revealed that its attempt is a potential vaccine against COVID-19 that is being developed with AstraZeneca could be set for regulators this year if scientists can gather enough data. The Oxford vaccine, as it is commonly known, showed early promise in the first human test when it produced an immune response, underlining its position as one of the leading candidates in the race to help people vaccinate against it. deadly novel coronavirus.
Also read:
Two hospitals in TN join Oxford Varsity in human trial against Covishield vaccine
Covishield: Phase 2 trial of Oxford COVID-19 vaccine candidate launches today
NEET, JEE Exam 2020 LIVE: Several top executives demand Center to postpone the exam
